Tricyclic Compound Mitochondrial Benzodiazepine Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stress-related diseases often have limitations such as side effects and addiction, and there is a need for a compound with superior oral absorption that can effectively target mitochondrial benzodiazepine receptors to regulate neurosteroid production and balance the excitatory and inhibitory signaling systems.
Innovation Solution
Development of specific tricyclic heterocyclic compounds, including those represented by formula (I), which have affinity for mitochondrial benzodiazepine receptors and exhibit strong anti-stress effects with superior oral absorption, as potential therapeutic agents for stress-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-stress drugs (antidepressants, anti-anxiety drugs) are used, then psychological stress symptoms are alleviated to some extent, but side effects and addiction frequently develop
Solution Approach 1:
The patent introduces mitochondrial benzodiazepine receptors (MBRs) as an intermediary target. Instead of directly acting on conventional neurotransmitter systems that cause side effects, the compound modulates neurosteroid production through MBRs, which then indirectly regulate the excitatory-inhibitory balance. This intermediary mechanism achieves therapeutic effects while avoiding direct harmful interactions with traditional drug targets.
Solution Approach 2:
The patent changes the therapeutic parameter from direct neurotransmitter modulation to neurosteroid production regulation. By targeting the biochemical pathway (cholesterol → pregnenolone → neurosteroids) rather than neurotransmitter receptors, the treatment achieves stress-related disease relief through a different physiological parameter, reducing side effects and addiction potential.
2Reliability
If compounds with affinity for mitochondrial benzodiazepine receptors are developed, then neurosteroid production can be regulated to balance signaling systems, but oral absorption needs to be improved
Solution Approach 1:
The patent optimizes the chemical parameters of the tricyclic compound structure (formula I) to improve oral bioavailability. By modifying molecular weight, lipophilicity, and structural features within specific ranges, the compound achieves sufficient blood-brain barrier penetration and oral absorption while maintaining affinity for mitochondrial benzodiazepine receptors and signaling system balancing effects.
Data Source
AI summary
The present invention relates to the compound represented by formula (I):(wherein, all the symbols has the same meanings as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof.Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.